Stroke Prevention in Atrial Fibrillation Study. Final results - PubMed (original) (raw)
Clinical Trial
Stroke Prevention in Atrial Fibrillation Study. Final results
No authors listed. Circulation. 1991 Aug.
Abstract
Background: Atrial fibrillation in the absence of rheumatic valvular disease is associated with a fivefold to sevenfold increased risk of ischemic stroke.
Methods and main results: The Stroke Prevention in Atrial Fibrillation Study, a multicenter, randomized trial, compared 325 mg/day aspirin (double-blind) or warfarin with placebo for prevention of ischemic stroke and systemic embolism (primary events), and included 1,330 inpatients and outpatients with constant or intermittent atrial fibrillation. During a mean follow-up of 1.3 years, the rate of primary events in patients assigned to placebo was 6.3% per year and was reduced by 42% in those assigned to aspirin (3.6% per year; p = 0.02; 95% confidence interval, 9-63%). In the subgroup of warfarin-eligible patients (most less than 76 years old), warfarin dose-adjusted to prolong prothrombin time to 1.3-fold to 1.8-fold that of control reduced the risk of primary events by 67% (warfarin versus placebo, 2.3% versus 7.4% per year; p = 0.01; 95% confidence interval, 27-85%). Primary events or death were reduced 58% (p = 0.01) by warfarin and 32% (p = 0.02) by aspirin. The risk of significant bleeding was 1.5%, 1.4%, and 1.6% per year in patients assigned to warfarin, aspirin, and placebo, respectively.
Conclusions: Aspirin and warfarin are both effective in reducing ischemic stroke and systemic embolism in patients with atrial fibrillation. Because warfarin-eligible patients composed a subset of all aspirin-eligible patients, the magnitude of reduction in events by warfarin versus aspirin cannot be compared. Too few events occurred in warfarin-eligible patients to directly assess the relative benefit of aspirin compared with warfarin, and the trial is continuing to address this issue. Patients with nonrheumatic atrial fibrillation who can safely take either aspirin or warfarin should receive prophylactic antithrombotic therapy to reduce the risk of stroke.
Comment in
- Stroke prevention in atrial fibrillation trial.
Cairns JA. Cairns JA. Circulation. 1991 Aug;84(2):933-5. doi: 10.1161/01.cir.84.2.933. Circulation. 1991. PMID: 1860238 No abstract available.
Similar articles
- Preliminary report of the Stroke Prevention in Atrial Fibrillation Study.
Stroke Prevention in Atrial Fibrillation Study Group Investigators. Stroke Prevention in Atrial Fibrillation Study Group Investigators. N Engl J Med. 1990 Mar 22;322(12):863-8. doi: 10.1056/NEJM199003223221232. N Engl J Med. 1990. PMID: 2407959 Clinical Trial. - Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
[No authors listed] [No authors listed] Arch Intern Med. 1996 Feb 26;156(4):409-16. Arch Intern Med. 1996. PMID: 8607726 Clinical Trial. - Anticoagulant therapy for atrial fibrillation. Recommendations from major studies.
Kahn JK. Kahn JK. Postgrad Med. 1992 Sep 1;92(3):119-24, 129-30. doi: 10.1080/00325481.1992.11701444. Postgrad Med. 1992. PMID: 1518749 Review. - Antithrombotic therapy in atrial fibrillation.
Turpie AG, Connolly SJ. Turpie AG, et al. Can Fam Physician. 1996 Jul;42:1341-5. Can Fam Physician. 1996. PMID: 8754703 Free PMC article. Review.
Cited by
- Left Atrial Appendage Occlusion: Current Stroke Prevention Strategies and a Shift Toward Data-Driven, Patient-Specific Approaches.
Mendez K, Kennedy DG, Wang DD, O'Neill B, Roche ET. Mendez K, et al. J Soc Cardiovasc Angiogr Interv. 2022 Jul 13;1(5):100405. doi: 10.1016/j.jscai.2022.100405. eCollection 2022 Sep-Oct. J Soc Cardiovasc Angiogr Interv. 2022. PMID: 39131471 Free PMC article. Review. - Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: assessing net clinical benefit.
McIntyre WF, Benz AP, Tojaga N, Brandes A, Lopes RD, Healey JS. McIntyre WF, et al. Eur Heart J Suppl. 2024 Jul 31;26(Suppl 4):iv4-iv11. doi: 10.1093/eurheartjsupp/suae075. eCollection 2024 Jul. Eur Heart J Suppl. 2024. PMID: 39099575 Free PMC article. - Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial.
Verburg A, Bor WL, Küçük IT, Henriques JPS, Vink MA, Ruifrok WT, Plomp J, Heestermans TACM, Schotborgh CE, Vlaar PJ, Magro M, Rikken SAOF, van den Broek WWA, van Mieghem CAG, Cornelis K, Rosseel L, Dujardin KS, Vandeloo B, Vandendriessche T, Ferdinande B, van 't Hof AWJ, Tijssen JGP, Limbruno U, De Caterina R, Rubboli A, Angiolillo DJ, Adriaenssens T, Dewilde W, Ten Berg JM. Verburg A, et al. EuroIntervention. 2024 Jul 15;20(14):e898-e904. doi: 10.4244/EIJ-D-24-00100. EuroIntervention. 2024. PMID: 39007830 - Support for Thrombolytic Therapy for Acute Stroke Patients on Direct Oral Anticoagulants: Mortality and Bleeding Complications.
Koscumb P, Murphy L, Talbott M, Nuti S, Golovko G, Shaltoni H, Jehle D. Koscumb P, et al. West J Emerg Med. 2024 May;25(3):399-406. doi: 10.5811/westjem.18063. West J Emerg Med. 2024. PMID: 38801047 Free PMC article. - Atrial Fibrillation Burden: Impact on Stroke Risk and Beyond.
AlTurki A, Essebag V. AlTurki A, et al. Medicina (Kaunas). 2024 Mar 26;60(4):536. doi: 10.3390/medicina60040536. Medicina (Kaunas). 2024. PMID: 38674182 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical